Genfit SA (GNFT)
5.70
+0.09
(+1.60%)
USD |
NASDAQ |
Sep 27, 16:00
5.70
0.00 (0.00%)
After-Hours: 20:00
Genfit Research and Development Expense (Annual): 50.57M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 50.57M |
| December 31, 2022 | 37.85M |
| December 31, 2021 | 41.71M |
| December 31, 2020 | 67.60M |
| December 31, 2019 | 74.14M |
| December 31, 2018 | 79.14M |
| Date | Value |
|---|---|
| December 31, 2017 | 61.38M |
| December 31, 2016 | 21.24M |
| December 31, 2015 | 5.980M |
| December 31, 2014 | 12.00M |
| December 31, 2013 | 6.855M |
| December 31, 2012 | 5.515M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
37.85M
Minimum
2022
74.14M
Maximum
2019
54.37M
Average
50.57M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Edap TMS SA | 7.538M |
| DBV Technologies SA | 60.22M |
| Cellectis SA | 87.65M |
| Ascendis Pharma AS | 447.61M |
| Adaptimmune Therapeutics PLC | 126.51M |